198 related articles for article (PubMed ID: 30527810)
1. Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers.
Rago F; DiMare MT; Elliott G; Ruddy DA; Sovath S; Kerr G; Bhang HC; Jagani Z
Biochem Biophys Res Commun; 2019 Jan; 508(1):109-116. PubMed ID: 30527810
[TBL] [Abstract][Full Text] [Related]
2. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.
Papillon JPN; Nakajima K; Adair CD; Hempel J; Jouk AO; Karki RG; Mathieu S; Möbitz H; Ntaganda R; Smith T; Visser M; Hill SE; Hurtado FK; Chenail G; Bhang HC; Bric A; Xiang K; Bushold G; Gilbert T; Vattay A; Dooley J; Costa EA; Park I; Li A; Farley D; Lounkine E; Yue QK; Xie X; Zhu X; Kulathila R; King D; Hu T; Vulic K; Cantwell J; Luu C; Jagani Z
J Med Chem; 2018 Nov; 61(22):10155-10172. PubMed ID: 30339381
[TBL] [Abstract][Full Text] [Related]
4. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
5. Targeting of BRM Sensitizes
Zernickel E; Sak A; Riaz A; Klein D; Groneberg M; Stuschke M
Mol Cancer Ther; 2019 Mar; 18(3):656-666. PubMed ID: 30478150
[TBL] [Abstract][Full Text] [Related]
6. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
7. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
8. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma.
Song S; Nguyen V; Schrank T; Mulvaney K; Walter V; Wei D; Orvis T; Desai N; Zhang J; Hayes DN; Zheng Y; Major MB; Weissman BE
Mol Cancer Res; 2020 Dec; 18(12):1777-1788. PubMed ID: 32855269
[TBL] [Abstract][Full Text] [Related]
9. PROTACs Targeting BRM (SMARCA2) Afford Selective
Berlin M; Cantley J; Bookbinder M; Bortolon E; Broccatelli F; Cadelina G; Chan EW; Chen H; Chen X; Cheng Y; Cheung TK; Davenport K; DiNicola D; Gordon D; Hamman BD; Harbin A; Haskell R; He M; Hole AJ; Januario T; Kerry PS; Koenig SG; Li L; Merchant M; Pérez-Dorado I; Pizzano J; Quinn C; Rose CM; Rousseau E; Soto L; Staben LR; Sun H; Tian Q; Wang J; Wang W; Ye CS; Ye X; Zhang P; Zhou Y; Yauch R; Dragovich PS
J Med Chem; 2024 Jan; 67(2):1262-1313. PubMed ID: 38180485
[TBL] [Abstract][Full Text] [Related]
10. Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia.
Rago F; Rodrigues LU; Bonney M; Sprouffske K; Kurth E; Elliott G; Ambrose J; Aspesi P; Oborski J; Chen JT; McDonald ER; Mapa FA; Ruddy DA; Kauffmann A; Abrams T; Bhang HC; Jagani Z
Mol Cancer Res; 2022 Mar; 20(3):361-372. PubMed ID: 34799403
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
Sun A; Tawfik O; Gayed B; Thrasher JB; Hoestje S; Li C; Li B
Prostate; 2007 Feb; 67(2):203-13. PubMed ID: 17075831
[TBL] [Abstract][Full Text] [Related]
12. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.
Hoffman GR; Rahal R; Buxton F; Xiang K; McAllister G; Frias E; Bagdasarian L; Huber J; Lindeman A; Chen D; Romero R; Ramadan N; Phadke T; Haas K; Jaskelioff M; Wilson BG; Meyer MJ; Saenz-Vash V; Zhai H; Myer VE; Porter JA; Keen N; McLaughlin ME; Mickanin C; Roberts CW; Stegmeier F; Jagani Z
Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3128-33. PubMed ID: 24520176
[TBL] [Abstract][Full Text] [Related]
13. SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines.
Ehrenhöfer-Wölfer K; Puchner T; Schwarz C; Rippka J; Blaha-Ostermann S; Strobl U; Hörmann A; Bader G; Kornigg S; Zahn S; Sommergruber W; Schweifer N; Zichner T; Schlattl A; Neumüller RA; Shi J; Vakoc CR; Kögl M; Petronczki M; Kraut N; Pearson MA; Wöhrle S
Sci Rep; 2019 Aug; 9(1):11661. PubMed ID: 31406271
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.
Kothandapani A; Gopalakrishnan K; Kahali B; Reisman D; Patrick SM
Exp Cell Res; 2012 Oct; 318(16):1973-86. PubMed ID: 22721696
[TBL] [Abstract][Full Text] [Related]
15. BRG1 and BRM function antagonistically with c-MYC in adult cardiomyocytes to regulate conduction and contractility.
Willis MS; Holley DW; Wang Z; Chen X; Quintana M; Jensen BC; Tannu M; Parker J; Jeyaraj D; Jain MK; Wolfram JA; Lee HG; Bultman SJ
J Mol Cell Cardiol; 2017 Apr; 105():99-109. PubMed ID: 28232072
[TBL] [Abstract][Full Text] [Related]
16. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.
Tagal V; Wei S; Zhang W; Brekken RA; Posner BA; Peyton M; Girard L; Hwang T; Wheeler DA; Minna JD; White MA; Gazdar AF; Roth MG
Nat Commun; 2017 Jan; 8():14098. PubMed ID: 28102363
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma.
Endo M; Yasui K; Zen Y; Gen Y; Zen K; Tsuji K; Dohi O; Mitsuyoshi H; Tanaka S; Taniwaki M; Nakanuma Y; Arii S; Yoshikawa T
Liver Int; 2013 Jan; 33(1):105-17. PubMed ID: 23088494
[TBL] [Abstract][Full Text] [Related]
18. Co-regulation of transcription by BRG1 and BRM, two mutually exclusive SWI/SNF ATPase subunits.
Raab JR; Runge JS; Spear CC; Magnuson T
Epigenetics Chromatin; 2017 Dec; 10(1):62. PubMed ID: 29273066
[TBL] [Abstract][Full Text] [Related]
19. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
Glaros S; Cirrincione GM; Muchardt C; Kleer CG; Michael CW; Reisman D
Oncogene; 2007 Oct; 26(49):7058-66. PubMed ID: 17546055
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.
Medina PP; Sanchez-Cespedes M
Epigenetics; 2008; 3(2):64-8. PubMed ID: 18437052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
